Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37145
Title: | Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect | Authors: | Bliuc, Dana Tran , Thach Adachi, Jonathan D. Atkins, Gerald J. Berger, Claudie VAN DEN BERGH, Joop Cappai , Roberto Eisman, John A. van Geel , Tineke GEUSENS, Piet Goltzman, David Hanley, David A. Josse, Robert Kaiser, Stephanie Kovacs, Christopher S. Langsetmo, Lisa Prior, Jerilynn C. Nguyen, Tuan, V Solomon, Lucian B. Stapledon, Catherine Center, Jacqueline R. |
Issue Date: | 2022 | Publisher: | WILEY | Source: | JOURNAL OF BONE AND MINERAL RESEARCH, | Status: | Early view | Abstract: | To the Editors: We are grateful to Dr. Naharci for the interest in our study reporting the association between cognitive decline and bone loss and fracture risk. (1) We agree that bisphosphonates (BPs) have a proven effect on reducing bone loss and fracture risk. (2) Medication with anticholinergic (ACH) side effects may also affect cogni-tive function as well as propensity to fall and fracture, although these effects have not been demonstrated in all studies. (3) We did not include these medication classes in our models because in observational studies the relationship between medication and outcomes is likely driven by factors associated with medication use. This bias by indication can only be avoided by specific study design (ie, propensity score matching), which was beyond the scope of our study. (4) However, we have conducted additional analyses to determine the prevalence of BP and ACH medication in our cohort, the association between these medication classes and our study outcomes and the impact of the addition of these medication classes to our findings. BP and ACH use were self-reported and obtained by questionnaire at baseline, and years 5 and 10. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry (DXA) and cognitive function using the Mini Mental State Examination (MMSE) test during all clinical visits. Follow-up time for BMD | Notes: | Bliuc, D (corresponding author), Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia. d.bliuc@garvan.org.au |
Document URI: | http://hdl.handle.net/1942/37145 | ISSN: | 0884-0431 | e-ISSN: | 1523-4681 | DOI: | 10.1002/jbmr.4530 | ISI #: | WOS:000768547700001 | Rights: | 2022 American Society for Bone and Mineral Research (ASBMR). | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Reply to_ The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect.pdf Restricted Access | Published version | 299.05 kB | Adobe PDF | View/Open Request a copy |
Page view(s)
30
checked on Sep 7, 2022
Download(s)
4
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.